A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective. READ MORE
News
A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective.
A recent study identified patient characteristics that help predict poor 3-year survival in newly diagnosed standard-risk multiple myeloma.
High levels of a specific enzyme are linked with lower survival rates in patients with multiple myeloma, according to a new study.
Adding a specific class of inhibitors to multiple myeloma treatment may not improve survival outcomes, but it does reduce overall pain and vertebral fractures.
Features
Researchers tested Bortezomib Administration on Treatment Outcomes in patients with myeloma.
Author Insights
Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.
Research in Review
The Levine Cancer Institute of the Carolinas HealthCare System has had a large impact on hematopoietic cell transplant outcomes.
Special Reports
The final section of the special report speculates on the future treatment landscape for relapsed or refractory multiple myeloma.
The fourth section of the report reviews the economic implications of a multiple myeloma diagnosis.
The next section of the report analyzes how clinical pathways support evidence-based treatment decision making for multiple myeloma.
The second section of the report explores the challenges of treatment resistance and relapse in multiple myeloma.
Resources
The National Comprehensive Cancer Network has implemented categories of preference for recommendations within their clinical practice guidelines in oncology.
